The shares of a leading mid-cap pharmaceutical company, known for its strong presence in API manufacturing, gained over 8 percent after the company announced the successful completion of a USFDA inspection at its Central Laboratory in Telangana with zero observations.
With a market capitalization of Rs 2,215 Crores, the share price of SMS Pharmaceuticals Ltd was trading almost 8% up to hit an intraday high of Rs 258.35 per share from its previous closing price of Rs 239.05 per share.
SMS Pharmaceuticals, in a stock exchange filing, said that the US FDA recently inspected its Central Laboratory Analytical Services in Gagillapur, Hyderabad, from June 23 to June 25, 2025. The inspection was completed with no issues or observations, meaning the facility met all required standards.
This was the second successful inspection by the USFDA at this lab. The company said it remains fully committed to maintaining high quality and following all necessary rules at its labs and manufacturing sites.
SMS Pharmaceuticals Ltd is one of India’s leading pharmaceutical companies, known for making high-quality Active Pharmaceutical Ingredients (APIs). It started in 1990 as a small, single-product unit and has now grown into a large company with four manufacturing facilities and two research centers.
The company has a strong presence in both Indian and global markets, with over 1,000 employees. Its facilities in Hyderabad and Vizag meet top international standards like cGMP and WHO. SMS also has the largest single-block Ibuprofen plant in Asia and focuses heavily on research and development (R&D).
It exports to many countries and was given export house status in 1997-98. SMS is also investing Rs 250 crore in expanding its capacity and has formed a joint venture with Spanish pharma company Chemo Iberica S.A. to grow its contract manufacturing business.
The company reported a revenue of Rs 783 crore in FY25, up by 10.44 percent from its FY24 revenue of Rs 709 crore. Coming to its profitability, the company reported a net profit rise of 38 percent to Rs 69 crore in FY25 from Rs 50 crore in FY24.
The stock delivered an ROE and ROCE of 11.8 percent and 12.6 percent, respectively, and the Promoter holding has also been increased by 1.58% over the last quarter.
Written By Rohan Pandey
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
